Rep. Lisa C. McClain Purchases Shares of Thermo Fisher Scientific Inc. (NYSE:TMO)

Key Points

• Rep. Lisa C. McClain purchased shares of Thermo Fisher Scientific Inc. (NYSE:TMO) valued between $1,001 and $15,000 on July 22nd, 2025.
• Thermo Fisher recently reported quarterly earnings with an EPS of $5.36, exceeding analysts' expectations and showing a 2.9% increase in revenue year-over-year.
• The company declared a quarterly dividend of $0.43 per share, with an annualized yield of 0.4%, set to be paid on October 15th to investors on record by September 15th.

Representative Lisa C. McClain (R-Michigan) recently bought shares of Thermo Fisher Scientific Inc. NYSE: TMO. In a filing disclosed on August 13th, the Representative disclosed that they had bought between $1,001 and $15,000 in Thermo Fisher Scientific stock on July 22nd. The trade occurred in the Representative's "CHARLES SCHWAB BROKERAGE ACCOUNT 924" account.

Representative Lisa C. McClain also recently made the following trade(s):

• Sold $1,001 - $15,000 in shares of Autoliv NYSE: ALV on 8/4/2025.
• Sold $1,001 - $15,000 in shares of Amazon.com NASDAQ: AMZN on 8/4/2025.
• Sold $1,001 - $15,000 in shares of Applied Materials NASDAQ: AMAT on 8/4/2025.
• Sold $1,001 - $15,000 in shares of Arthur J. Gallagher & Co. NYSE: AJG on 8/4/2025.
• Sold $1,001 - $15,000 in shares of SAP NYSE: SAP on 7/22/2025.
• Purchased $1,001 - $15,000 in shares of XPO NYSE: XPO on 7/22/2025.
• Purchased $1,001 - $15,000 in shares of Lithia Motors NYSE: LAD on 7/22/2025.
• Sold $1,001 - $15,000 in shares of Sanofi NASDAQ: SNY on 7/22/2025.
• Sold $1,001 - $15,000 in shares of Waters NYSE: WAT on 7/22/2025.
• Purchased $1,001 - $15,000 in shares of Group 1 Automotive NYSE: GPI on 7/22/2025.

Thermo Fisher Scientific Stock Performance

Thermo Fisher Scientific stock traded up $4.92 during trading on Friday, reaching $489.96. The company had a trading volume of 2,462,453 shares, compared to its average volume of 3,059,810. Thermo Fisher Scientific Inc. has a 52 week low of $385.46 and a 52 week high of $627.88. The firm's 50-day simple moving average is $434.83 and its 200 day simple moving average is $459.02. The firm has a market capitalization of $185.01 billion, a price-to-earnings ratio of 28.34, a price-to-earnings-growth ratio of 2.61 and a beta of 0.74. The company has a current ratio of 1.93, a quick ratio of 1.50 and a debt-to-equity ratio of 0.65.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last announced its earnings results on Wednesday, July 23rd. The medical research company reported $5.36 EPS for the quarter, topping analysts' consensus estimates of $5.22 by $0.14. The company had revenue of $10.86 billion for the quarter, compared to analysts' expectations of $10.68 billion. Thermo Fisher Scientific had a return on equity of 16.82% and a net margin of 15.24%. Thermo Fisher Scientific's revenue for the quarter was up 2.9% compared to the same quarter last year. During the same period last year, the firm earned $5.37 EPS. Sell-side analysts forecast that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current fiscal year.

Thermo Fisher Scientific Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Wednesday, October 15th. Stockholders of record on Monday, September 15th will be paid a $0.43 dividend. This represents a $1.72 dividend on an annualized basis and a dividend yield of 0.4%. The ex-dividend date is Monday, September 15th. Thermo Fisher Scientific's dividend payout ratio (DPR) is 9.95%.

Wall Street Analyst Weigh In

A number of equities research analysts have commented on TMO shares. Royal Bank Of Canada decreased their price target on Thermo Fisher Scientific from $651.00 to $637.00 and set an "outperform" rating on the stock in a report on Thursday, April 24th. Wall Street Zen cut Thermo Fisher Scientific from a "buy" rating to a "hold" rating in a report on Sunday, August 10th. HSBC restated a "hold" rating and set a $510.00 price objective on shares of Thermo Fisher Scientific in a research report on Thursday, July 24th. Barclays raised their price objective on Thermo Fisher Scientific from $450.00 to $490.00 and gave the company an "equal weight" rating in a research report on Thursday, July 24th. Finally, UBS Group raised their price objective on Thermo Fisher Scientific from $460.00 to $500.00 and gave the company a "neutral" rating in a research report on Thursday, July 24th. Seven analysts have rated the stock with a hold rating and fifteen have issued a buy rating to the company's stock. According to MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $593.00.

Insiders Place Their Bets

In other Thermo Fisher Scientific news, EVP Gianluca Pettiti sold 400 shares of the company's stock in a transaction on Friday, July 25th. The shares were sold at an average price of $479.98, for a total value of $191,992.00. Following the sale, the executive vice president directly owned 22,367 shares of the company's stock, valued at approximately $10,735,712.66. This represents a 1.76% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Marc N. Casper sold 8,000 shares of the stock in a transaction dated Thursday, August 7th. The stock was sold at an average price of $454.45, for a total transaction of $3,635,600.00. Following the sale, the chief executive officer directly owned 115,174 shares in the company, valued at approximately $52,340,824.30. The trade was a 6.49% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 18,400 shares of company stock worth $8,345,792 over the last three months. Corporate insiders own 0.33% of the company's stock.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of the business. Vanguard Group Inc. raised its stake in shares of Thermo Fisher Scientific by 0.9% during the second quarter. Vanguard Group Inc. now owns 33,789,164 shares of the medical research company's stock valued at $13,700,154,000 after acquiring an additional 309,207 shares in the last quarter. Capital World Investors increased its position in shares of Thermo Fisher Scientific by 1.1% during the fourth quarter. Capital World Investors now owns 9,430,120 shares of the medical research company's stock worth $4,905,812,000 after purchasing an additional 104,343 shares in the last quarter. Norges Bank purchased a new stake in shares of Thermo Fisher Scientific during the second quarter valued at $2,264,615,000. Franklin Resources Inc. grew its holdings in shares of Thermo Fisher Scientific by 11.3% during the second quarter. Franklin Resources Inc. now owns 4,897,546 shares of the medical research company's stock valued at $1,985,759,000 after buying an additional 498,238 shares during the last quarter. Finally, Northern Trust Corp grew its holdings in shares of Thermo Fisher Scientific by 13.2% during the fourth quarter. Northern Trust Corp now owns 3,910,015 shares of the medical research company's stock valued at $2,034,107,000 after buying an additional 455,004 shares during the last quarter. Hedge funds and other institutional investors own 89.23% of the company's stock.

About Representative McClain

Lisa McClain (Republican Party) is a member of the U.S. House, representing Michigan's 9th Congressional District. She assumed office on January 3, 2023. Her current term ends on January 3, 2027. McClain (Republican Party) is running for re-election to the U.S. House to represent Michigan's 9th Congressional District. She declared candidacy for the 2026 election. Lisa McClain lives in Romeo, Michigan. McClain earned a bachelor's degree in business administration from Northwood University. Her career experience includes founding and working as the president of North End Support Team.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.